Five Years Since SUNBEAM: Has Ozanimod's Potential Succeeded?

PHARMACOLOGY

A phase 3 trial exists as a theory with compelling evidence supporting it. Long-term data is the verdict.

The 2019 SUNBEAM trial made a specific bet: that ozanimod, an oral sphingosine-1-phosphate receptor modulator, could exceed an established injectable therapy, interferon beta-1a, on both relapse activity and MRI lesion burden in relapsing multiple sclerosis (MS), without the cardiac safety concerns that shadowed prior drugs in its class. Researchers can only mildly guarantee a 12-month solo trial. What matters now, more than five years and multiple follow-up studies later, is whether that promise lasted.

What SUNBEAM Actually Discovered

SUNBEAM's initial design was a strict protocol: a randomized, double-blind, active-controlled trial involving 152 sites in 20 nations, employing the 2010 McDonald diagnostic criteria and the Expanded Disability Status Scale for consistent diagnosis and severity assessment among participants.

The results favored ozanimod on the trial's core measures — participants on ozanimod showed significantly lower annualized relapse rates and fewer new or enlarging brain lesions than those on interferon beta-1a, and the 1.0 mg dose outperformed the 0.5 mg dose on both counts while preserving more brain volume at 12 months. Reassuring cardiac monitoring data showed no cases of second- or third-degree heart block or heart rate reductions after the first dose, and symptoms stayed moderate.

Although it was an impressive 12-month result, it did not provide evidence that the drug would endure over years of real-world use — and that's precisely the divide subsequent research aimed to close.

DAYBREAK's Final Summary

DAYBREAK, the open-label expansion trial that followed ozanimod-treated patients from the original phase 1–3 studies, published its final report in 2025, comprising approximately 15,500 patient-years of exposure. The overall results presented sustained 12-month disease suppression from the original trials and, in some statistics, further improved over years of continued treatment. Relapses remained low, disability progression narrowed, and MRI lesion counts declined.

The safety profile remained consistent. Across the full DAYBREAK follow-up, infection rates — including herpes, a recognized burden with this drug class — reduced rather than advanced. Only one verified case of progressive multifocal leukoencephalopathy (PML) emerged across the entire ozanimod expansion program, with few cardiac adverse events, and no evidence that risk increased with continued exposure. That's a significant and well-deserved verdict for a drug class where cardiac tolerability was the main unresolved issue in 2019.

What Real-World Data Says That a Trial Can't

Clinical trials recruit meticulously screened populations under close supervision; real-world data captures results when a drug reaches normal patients with normal adherence patterns.

A 2026 study of ozanimod use across two tertiary MS centers found 72% of patients continued on the drug at 12 months, with the annualized relapse rate falling 56% from each patient's own pre-treatment standard. New or enlarging MRI lesions fell from 40% of patients to 6.6%, and gadolinium-enhancing lesions dropped from 27% to under 4%, measurements that track closely with what SUNBEAM originally reported, despite a minimal controlled setting.

At the 2026 Consortium of Multiple Sclerosis Centers convention, a distinct three-year German real-world study emphasized comparable results of minimal relapse activity, unchanged disability, and consistent cognitive performance over time, an aspect SUNBEAM did not extensively analyze.

What this Means for the Original Trial's Conclusions

Compared to several additional years of evidence, SUNBEAM's fundamental claims mostly reinforce rather than complicate the findings.

●       Efficacy durability: relapse and lesion reductions seen at 12 months persisted through years of continued treatment instead of declining.

●       Cardiac safety: the encouraging first-dose monitoring data from SUNBEAM predicted a low long-term cardiac risk.

●       Dose response: the advantage of the 1.0 mg dose over 0.5 mg, identified in SUNBEAM, has continued to show up in extension and real-world data.

The one long-term data point that adds meaningful nuance is discontinuation: approximately one quarter to one third of real-world patients who discontinue ozanimod do so because of adverse effects—a detail a single 12-month controlled trial could not capture. While this does not detract from the efficacy findings themselves, it provides important context when setting initial patient expectations.

Why SUNBEAM Still Resonates: The De-Escalation Question

MS care now grapples with a question SUNBEAM did not intend to answer but whose data is precisely relevant: what develops when a patient who has been stable for years on a high-efficacy anti-CD20 therapy — ocrelizumab, ofatumumab, or a similar B-cell depleting agent — prepares for something less aggressive?

Anti-CD20 therapies became the optimal choice for many patients because they are so effective, yet sustained B-cell depletion bears its own accruing costs: raised infection risk, hypogammaglobulinemia, and weakened vaccine responses after years of continuous treatment. Clinicians and researchers are now actively investigating de-escalation strategies for specifically this reason, and one candidate considered for that role is ozanimod.

A prospective study (COMIRB 23-1686) is evaluating ozanimod explicitly as a de-escalation therapy for MS patients on anti-CD20 treatment who have been clinically stable for several years. Comparisons of anti-CD20 maintenance versus de-escalation against platform therapies via a randomized non-inferiority trial, and broader 2025 reviews of anti-CD20 de-escalation strategies by other research groups are underway. These studies reflect a scientific community searching for evidence on how to suspend high-efficacy treatment without losing disease control.

This is precisely the context where SUNBEAM's original data now becomes timely, rather than only historically curious. A drug warranted as a de-escalation option needs two things: a vetted safety profile that endures long-term, real-world use, and bold enough efficacy data that doesn't mean replacing disease control.

SUNBEAM, reinforced by the DAYBREAK extension and the real-world disciples discussed previously, is accurately what gives ozanimod reputation in that conversation — durable relapse and lesion suppression, and a cardiac safety profile confirmed over years rather than months. Clinicians support dosing data transparent enough that they know what a full-strength regimen looks like before they ever consider using it as a step-down therapy.

SUNBEAM’s development was not to answer the de-escalation question, yet the field currently debating that question relies on the durability of SUNBEAM's original findings to do it.

The Universal Lesson

SUNBEAM was not the final word on ozanimod—no single phase 3 trial could be. Its true significance lies in what it accurately predicted: that efficacy would extend beyond 12 months and that ozanimod’s structural safety advantages over earlier S1P modulators would persist through years of real-world exposure. Multi-year extension data and independent real-world cohorts later validated both predictions.

References

Comi, G., Kappos, L., et al. (2019). Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial. The Lancet Neurology, 18, 1069–1080.

Selmaj, K. W., Steinman, L., Comi, G., Bar-Or, A., Arnold, D. L., Hartung, H.-P., Montalbán, X., Havrdová, E. K., Sheffield, J. K., Krakovich, A., Cheng, C.-Y., Riolo, J. V., Pachai, C., Thorpe, A., DeBoer, E., Kappos, L., Cohen, J. A., & Cree, B. A. C. (2025). Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial. Multiple Sclerosis Journal.

Real-world experience of ozanimod in adults with multiple sclerosis. (2026). Postgraduate Medicine.

NeurologyLive. (2026, May 28). Real-world ozanimod data in relapsing-remitting MS show

low relapse rates and stable disability over 3 years.

European Medical Journal. (2026, January 22). Rethinking early intervention in relapsing multiple sclerosis: A closer look at long-term safety and efficacy data for sphingosine 1- phosphate modulators.

University of Colorado / COMIRB. (2024–2025). Prospective evaluation of sequencing from anti-CD20 therapies to ozanimod (Study No. 23-1686).

Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis. (2025). Expert Opinion on Biological Therapy. doi:10.1080/14712598.2025.2501730

University Hospital, Montpellier. (2025). A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus de-escalation strategy in relapsing-remitting

multiple sclerosis (ClinicalTrials.gov Identifier NCT07189325). ClinicalTrials.gov.

---

Need writing like this for your organization?

See My Work